Locate Bio

Locate Bio is an innovative private biotech company building a diversified orthobiologics portfolio, with its lead candidate, LDGraft™, currently in clinical trials for spinal fusion. The company's strategy centers on developing biomimetic recombinant human BMP-2 (rhBMP-2) products and synthetic calcium phosphate scaffolds to dominate specific market segments in orthopedics and spine surgery. With a seasoned leadership team and an FDA Breakthrough Device designation for its lead program, Locate Bio is positioning itself as a future leader in the regenerative medicine space for musculoskeletal conditions.

Industry-leading drug delivery and tissue scaffold capabilities focused on biomimetic presentation of rhBMP-2 and synthetic calcium phosphate materials with instructive geometric clues for bone regeneration.

Locate Bio competes in the orthobiologics and spinal fusion market against major players like Medtronic (INFUSE® Bone Graft), Stryker, Johnson & Johnson (DePuy Synthes), and SeaSpine, as well as numerous bone graft substitute and allograft companies. Its strategy is to differentiate through biomimetic technology and improved product performance.